EX-99.1 2 tkno-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

img201297901_0.jpg 

 

Teknova Reports Third Quarter 2023 Financial Results

 

Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt

Third quarter 2023 total revenue was $8.2 million, down 24% from prior year

Expect 2023 revenue at the low end of previously announced guidance range of $37-40 million

 

 

HOLLISTER, Calif., November 9, 2023 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2023.

 

“Today we reported a solid third quarter, both financially and operationally, against a difficult market backdrop,” said Stephen Gunstream, President and Chief Executive Officer of Teknova. “We have expanded the use of our new state-of-the-art GMP facility to produce a variety of products, such as single-use bags and bottles, to meet the needs of customers in our target markets. While we continue to see emerging biotech customers conserving capital, we remain enthusiastic about our position in the market and the long-term potential of our business.”

 

“We are very pleased to have completed an equity capital raise of $22.9 million in September, which along with repayment of $10.0 million of debt strengthens our balance sheet. Through the third quarter of 2023, we have also managed our overall expenses and capital expenditures to plan and now expect full-year free cash outflow to be less than $30 million,” explained Matt Lowell, Teknova’s Chief Financial Officer.

 

Corporate Updates

 

Raised $22.9 million of equity capital through a registered direct offering and concurrent private placement, and paid down $10.0 million of long-term debt
Validated manufacturing processes and automation equipment in new GMP facility to be able to service nearly all bioprocessing customer needs, including standard-use bottles and 1 L to 200 L single-use bags
Launched an additional version of our first-of-its-kind AEX Buffer Screening Kit for the AAV6 serotype as part of our proprietary product line, AAV-Tek Solutions, along with more than 60 off-the-shelf reagents to help expedite plasmid production across the entire workflow

1

 


Revenue for the Third Quarter and Year-to-Date

 

 

 

For the Three Months Ended
September 30,

 

 

For the Nine Months Ended
September 30,

 

(Dollars in thousands)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Lab Essentials

 

$

7,274

 

 

$

9,470

 

 

$

22,112

 

 

$

24,838

 

Clinical Solutions

 

 

597

 

 

 

919

 

 

 

5,859

 

 

 

7,673

 

Other

 

 

298

 

 

 

303

 

 

 

846

 

 

 

1,018

 

Total revenue

 

$

8,169

 

 

$

10,692

 

 

$

28,817

 

 

$

33,529

 

 

Third Quarter 2023 Financial Results

 

Total revenue for the third quarter 2023 was $8.2 million, down 24% compared to $10.7 million in the third quarter 2022. Lab Essentials revenue was $7.3 million in the third quarter 2023, down 23% compared to $9.5 million in the third quarter 2022. Clinical Solutions revenue was $0.6 million, down 35% compared to $0.9 million in the third quarter 2022.

Gross profit for the third quarter 2023 was $1.5 million, compared to $4.8 million in the third quarter 2022. Gross margin for the third quarter 2023 was 18.0%, compared to 44.6% in the third quarter 2022. The decrease in gross profit percentage was driven primarily by the decrease in revenue and the associated lower absorption of fixed manufacturing costs, and to a lesser extent by increased overhead costs, which were partially offset by reduced headcount.

Operating expenses for the third quarter 2023 were $10.2 million, compared to $27.7 million in the third quarter 2022. Excluding the non-recurring, non-cash charges of $0.4 million in the third quarter 2023 related to the write-off of ATM Facility offering costs and the $16.6 million goodwill impairment charge recorded in the third quarter 2022, operating expenses were down $1.3 million in the third quarter 2023 compared to the third quarter 2022. The decrease was driven primarily by reduced headcount and spending, in particular in professional fees.

Net loss for the third quarter 2023 was $10.2 million, or negative $0.34 per diluted share, compared to $22.5 million, or negative $0.80 per diluted share, for the third quarter 2022.

Adjusted EBITDA for the third quarter 2023 was negative $5.5 million, compared to negative $4.6 million for the third quarter 2022. Free Cash Flow was negative $5.4 million for the third quarter 2023, compared to negative $14.9 million for the third quarter 2022.

 

2023 Outlook

 

Teknova now anticipates that revenue will be at the low end of its $37 million to $40 million guidance range for the fiscal year ending December 31, 2023 (“2023”). The Company now anticipates free cash outflow to be less than its previously communicated target of $30 million for 2023.

 

2

 


Upcoming Investor Conference Presentations

 

Stephens Annual Investment Conference

Wednesday, November 15th, 2023 at 4:00 p.m. ET

 

35th Annual Piper Sandler Healthcare Conference

Wednesday, November 29th, 2023 at 8:30 a.m. ET

 

Conference Call and Webcast

 

Teknova will host a webcast and conference call on Thursday, November 9, 2023, beginning at 5:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/nsccw7hr. To receive a PIN for dialing in, participants can register for the webcast via this link: https://register.vevent.com/register/BI43a2f4610cbe41f5b78f7d61007caf37. The webcast will be available for replay on the Company’s website approximately two hours after the event.

 

About Teknova

 

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers, reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

 

Non-GAAP Financial Measures

 

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.

 

Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.

 

3

 


Teknova defines Free Cash Flow as cash used in operating activities less purchases of property, plant, and equipment.

 

Teknova provides Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

 

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

 

Forward-Looking Statements

 

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2023 revenue and free cash outflow guidance, expected growth in Lab Essentials and Clinical Solutions, ongoing capacity expansion, new research and development products, prospects, including to achieve profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s ability to expand its production, commercial, and research and development capabilities; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the lingering impacts of the COVID-19 pandemic and the conflicts in Ukraine and the Middle East; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent Quarterly Reports on Form

4

 


10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

Investor Contacts Media Contact

Matt Lowell Jennifer Henry

Chief Financial Officer Senior Vice President, Marketing

matt.lowell@teknova.com jenn.henry@teknova.com

+1 831-637-1100 +1 831-313-1259

Sara Michelmore

MacDougall Advisors

smichelmore@macdougall.bio

+1 781-235-3060

 

 

5

 


ALPHA TEKNOVA, INC.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

 

 

 

For the Three Months Ended
September 30,

 

 

For the Nine Months Ended
September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue

 

$

8,169

 

 

$

10,692

 

 

$

28,817

 

 

$

33,529

 

Cost of sales

 

 

6,697

 

 

 

5,922

 

 

 

19,856

 

 

 

18,163

 

Gross profit

 

 

1,472

 

 

 

4,770

 

 

 

8,961

 

 

 

15,366

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

1,397

 

 

 

1,925

 

 

 

4,256

 

 

 

5,867

 

Sales and marketing

 

 

2,412

 

 

 

2,397

 

 

 

6,929

 

 

 

6,592

 

General and administrative

 

 

6,138

 

 

 

6,502

 

 

 

19,426

 

 

 

20,856

 

Amortization of intangible assets

 

 

287

 

 

 

287

 

 

 

860

 

 

 

861

 

Long-lived assets impairment

 

 

 

 

 

 

 

 

2,195

 

 

 

 

Goodwill impairment

 

 

 

 

 

16,613

 

 

 

 

 

 

16,613

 

Total operating expenses

 

 

10,234

 

 

 

27,724

 

 

 

33,666

 

 

 

50,789

 

Loss from operations

 

 

(8,762

)

 

 

(22,954

)

 

 

(24,705

)

 

 

(35,423

)

Other (expenses) income, net

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense) income, net

 

 

(791

)

 

 

70

 

 

 

(1,006

)

 

 

85

 

Loss on extinguishment of debt

 

 

(824

)

 

 

 

 

 

(824

)

 

 

 

Other income, net

 

 

233

 

 

 

36

 

 

 

417

 

 

 

36

 

Total other (expenses) income, net

 

 

(1,382

)

 

 

106

 

 

 

(1,413

)

 

 

121

 

Loss before income taxes

 

 

(10,144

)

 

 

(22,848

)

 

 

(26,118

)

 

 

(35,302

)

Provision for (benefit from) income taxes

 

 

9

 

 

 

(374

)

 

 

6

 

 

 

(1,128

)

Net loss

 

$

(10,153

)

 

$

(22,474

)

 

$

(26,124

)

 

$

(34,174

)

Net loss per share—basic and diluted

 

$

(0.34

)

 

$

(0.80

)

 

$

(0.91

)

 

$

(1.22

)

Weighted average shares used in computing net loss per share—basic and diluted

 

 

29,956,930

 

 

 

28,090,267

 

 

 

28,810,068

 

 

 

28,059,897

 

 

 

6

 


ALPHA TEKNOVA, INC.

Condensed Balance Sheets

(Unaudited)

(In thousands)

 

 

 

As of September 30,

 

 

As of December 31,

 

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

32,079

 

 

$

42,236

 

Accounts receivable, net

 

 

5,160

 

 

 

4,261

 

Inventories, net

 

 

11,468

 

 

 

12,247

 

Income taxes receivable

 

 

 

 

 

22

 

Prepaid expenses and other current assets

 

 

2,371

 

 

 

2,374

 

Total current assets

 

 

51,078

 

 

 

61,140

 

Property, plant, and equipment, net

 

 

51,579

 

 

 

51,577

 

Operating right-of-use lease assets

 

 

17,080

 

 

 

19,736

 

Intangible assets, net

 

 

16,696

 

 

 

17,556

 

Other non-current assets

 

 

1,952

 

 

 

2,252

 

Total assets

 

$

138,385

 

 

$

152,261

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

1,422

 

 

$

2,449

 

Accrued liabilities

 

 

5,147

 

 

 

6,203

 

Current portion of operating lease liabilities

 

 

1,770

 

 

 

2,223

 

Total current liabilities

 

 

8,339

 

 

 

10,875

 

Deferred tax liabilities

 

 

1,228

 

 

 

1,223

 

Other accrued liabilities

 

 

125

 

 

 

191

 

Long-term debt, net

 

 

13,168

 

 

 

21,976

 

Long-term operating lease liabilities

 

 

15,873

 

 

 

18,111

 

Total liabilities

 

 

38,733

 

 

 

52,376

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock

 

 

 

 

 

 

Common stock

 

 

 

 

 

 

Additional paid-in capital

 

 

180,782

 

 

 

154,891

 

Accumulated deficit

 

 

(81,130

)

 

 

(55,006

)

Total stockholders’ equity

 

 

99,652

 

 

 

99,885

 

Total liabilities and stockholders’ equity

 

$

138,385

 

 

$

152,261

 

 

 

7

 


ALPHA TEKNOVA, INC.

Condensed Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

For the Three Months Ended
September 30,

 

 

For the Nine Months Ended
September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(10,153

)

 

$

(22,474

)

 

$

(26,124

)

 

$

(34,174

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Bad debt expense

 

 

13

 

 

 

2

 

 

 

21

 

 

 

34

 

Inventory reserve

 

 

97

 

 

 

186

 

 

 

130

 

 

 

178

 

Depreciation and amortization

 

 

1,622

 

 

 

729

 

 

 

4,049

 

 

 

2,272

 

Stock-based compensation

 

 

1,035

 

 

 

968

 

 

 

3,115

 

 

 

2,689

 

Deferred taxes

 

 

9

 

 

 

(374

)

 

 

5

 

 

 

(1,125

)

Amortization of debt financing costs

 

 

205

 

 

 

60

 

 

 

415

 

 

 

159

 

Non-cash lease expense

 

 

55

 

 

 

75

 

 

 

86

 

 

 

256

 

Loss on disposal of property, plant, and equipment

 

 

5

 

 

 

210

 

 

 

5

 

 

 

210

 

Long-lived assets impairment

 

 

 

 

 

 

 

 

2,195

 

 

 

 

Goodwill impairment

 

 

 

 

 

16,613

 

 

 

 

 

 

16,613

 

Loss on extinguishment of debt

 

 

824

 

 

 

 

 

 

824

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

  Accounts receivable

 

 

(402

)

 

 

227

 

 

 

(721

)

 

 

(949

)

  Contract assets

 

 

1,050

 

 

 

(667

)

 

 

 

 

 

(667

)

  Inventories

 

 

453

 

 

 

(2,600

)

 

 

649

 

 

 

(5,107

)

  Income taxes receivable

 

 

22

 

 

 

(3

)

 

 

22

 

 

 

1,068

 

  Prepaid expenses and other current assets

 

 

(1,736

)

 

 

(1,820

)

 

 

(694

)

 

 

(1,083

)

  Other non-current assets

 

 

78

 

 

 

(407

)

 

 

300

 

 

 

(996

)

  Accounts payable

 

 

414

 

 

 

1,247

 

 

 

(948

)

 

 

969

 

  Accrued liabilities

 

 

2,049

 

 

 

(283

)

 

 

815

 

 

 

343

 

  Other

 

 

(22

)

 

 

(21

)

 

 

(66

)

 

 

(61

)

    Cash used in operating activities

 

 

(4,382

)

 

 

(8,332

)

 

 

(15,922

)

 

 

(19,371

)

Investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant, and equipment

 

 

(972

)

 

 

(6,582

)

 

 

(7,622

)

 

 

(23,419

)

    Cash used in investing activities

 

 

(972

)

 

 

(6,582

)

 

 

(7,622

)

 

 

(23,419

)

Financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from equity financing

 

 

22,915

 

 

 

 

 

 

22,915

 

 

 

 

Repayment of long-term debt

 

 

(10,000

)

 

 

 

 

 

(10,000

)

 

 

 

Proceeds from financed insurance premiums

 

 

1,004

 

 

 

 

 

 

1,004

 

 

 

 

Repayment of financed insurance premiums

 

 

(294

)

 

 

 

 

 

(294

)

 

 

 

Proceeds from long-term debt

 

 

 

 

 

 

 

 

 

 

 

5,135

 

Payment of debt issuance costs

 

 

 

 

 

 

 

 

(24

)

 

 

(151

)

Payment of exit fee costs

 

 

 

 

 

 

 

 

 

 

 

(135

)

Payment of ATM Facility costs

 

 

 

 

 

 

 

 

(395

)

 

 

 

Proceeds from exercise of stock options

 

 

 

 

 

35

 

 

 

76

 

 

 

134

 

Proceeds from issuance of common stock under employee stock purchase plan

 

 

 

 

 

 

 

 

138

 

 

 

144

 

    Cash provided by financing activities

 

 

13,625

 

 

 

35

 

 

 

13,420

 

 

 

5,127

 

Change in cash, cash equivalents, and restricted cash

 

 

8,271

 

 

 

(14,879

)

 

 

(10,124

)

 

 

(37,663

)

Cash, cash equivalents, and restricted cash at beginning of period

 

 

23,841

 

 

 

64,734

 

 

 

42,236

 

 

 

87,518

 

Cash, cash equivalents, and restricted cash at end of period

 

$

32,112

 

 

$

49,855

 

 

$

32,112

 

 

$

49,855

 

 

 

8

 


ALPHA TEKNOVA, INC.

Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures

(Unaudited)

(In thousands)

 

 

 

For the Three Months Ended
September 30,

 

 

For the Nine Months Ended
September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net loss – as reported

 

$

(10,153

)

 

$

(22,474

)

 

$

(26,124

)

 

$

(34,174

)

Add back:

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense) income, net

 

 

(791

)

 

 

70

 

 

 

(1,006

)

 

 

85

 

Provision for (benefit from) income taxes

 

 

9

 

 

 

(374

)

 

 

6

 

 

 

(1,128

)

Depreciation expense

 

 

1,335

 

 

 

442

 

 

 

3,189

 

 

 

1,411

 

Amortization of intangible assets

 

 

287

 

 

 

287

 

 

 

860

 

 

 

861

 

EBITDA

 

$

(7,731

)

 

$

(22,189

)

 

$

(21,063

)

 

$

(33,115

)

Other and non-recurring expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

1,035

 

 

 

968

 

 

 

3,115

 

 

 

2,689

 

Severance pay and other termination benefits

 

 

 

 

 

 

 

 

725

 

 

 

 

Long-lived assets impairment

 

 

 

 

 

 

 

 

2,195

 

 

 

 

Goodwill impairment

 

 

 

 

 

16,613

 

 

 

 

 

 

16,613

 

Loss on extinguishment of debt

 

 

824

 

 

 

 

 

 

824

 

 

 

 

Write-off of ATM Facility costs

 

 

395

 

 

 

 

 

 

395

 

 

 

 

Adjusted EBITDA

 

$

(5,477

)

 

$

(4,608

)

 

$

(13,809

)

 

$

(13,813

)

 

 

 

For the Three Months Ended
September 30,

 

 

For the Nine Months Ended
September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Cash used in operating activities

 

$

(4,382

)

 

$

(8,332

)

 

$

(15,922

)

 

$

(19,371

)

Purchase of property, plant, and equipment

 

 

(972

)

 

 

(6,582

)

 

 

(7,622

)

 

 

(23,419

)

Free Cash Flow

 

$

(5,354

)

 

$

(14,914

)

 

$

(23,544

)

 

$

(42,790

)

 

9